AbbVie (NYSE:ABBV) Releases Earnings Results, Beats Expectations By $0.09 EPS

AbbVie (NYSE:ABBV) announced its quarterly earnings data on Friday. The company reported $3.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.73 by $0.09, FiscalAI reports. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $17.40 billion during the quarter, compared to analyst estimates of $17.32 billion. During the same quarter in the prior year, the firm posted $1.86 earnings per share. AbbVie’s quarterly revenue was up 10.3% on a year-over-year basis.

Here are the key takeaways from AbbVie’s conference call:

• AbbVie raised its full-year outlook after third-quarter adjusted EPS of $3.82 and revenue of $17.4 billion exceeded expectations. Full-year revenue guidance increased by $200 million to approximately $67.8 billion, while adjusted EPS guidance rose to $13.95–$13.99.
• Immunology remained the primary growth engine, with SKYRIZI sales up 22.9% operationally to nearly $5.8 billion and RINVOQ sales up 24.3% to $2.7 billion. AbbVie expects further momentum from SKYRIZI’s newly approved subcutaneous Crohn’s induction regimen and potential RINVOQ approvals in vitiligo and alopecia areata.
• AbbVie highlighted several pipeline and portfolio catalysts, including FDA approval of JUVMO for Parkinson’s disease, positive phase III data for etentamig in multiple myeloma, and a 51% reduction in disease progression or death with EPKINLY plus R-CHOP in frontline DLBCL. Regulatory submissions and potential approvals are expected across these programs in 2027.
• Legacy and pressured businesses continued to weigh on results: HUMIRA sales fell 30.6% due to biosimilar competition, IMBRUVICA declined 26.1% amid IRA pricing and share pressure, and aesthetics revenue fell 1.8% as JUVÉDERM remained weak. AbbVie also expects a gradual JUVMO launch because broader Medicare coverage is not expected until 2028.
• Strong cash generation supported a 5.2% quarterly dividend increase to $1.82 per share and continued business-development capacity. Management said future deals are likely to be bolt-on acquisitions focused on differentiated assets in immunology, neuroscience, oncology, and obesity rather than another transformational transaction.

AbbVie Price Performance

Shares of ABBV stock opened at $294.80 on Friday. The firm has a market cap of $520.85 billion, a PE ratio of 50.74, a price-to-earnings-growth ratio of 1.35 and a beta of 0.24. The company has a 50-day moving average of $269.35 and a two-hundred day moving average of $237.23. AbbVie has a 1-year low of $190.75 and a 1-year high of $298.74.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a $1.73 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.3%. AbbVie’s dividend payout ratio is presently 195.48%.

Insider Buying and Selling at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.06% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several analysts have recently weighed in on ABBV shares. Canaccord Genuity Group increased their price target on shares of AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. UBS Group raised their price target on shares of AbbVie from $260.00 to $275.00 and gave the stock a “neutral” rating in a report on Tuesday, October 6th. Oppenheimer lifted their price target on shares of AbbVie from $244.00 to $258.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. Bank of America reiterated a “buy” rating on shares of AbbVie in a report on Tuesday, September 8th. Finally, Argus upped their price objective on AbbVie from $250.00 to $270.00 in a report on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and an average price target of $279.86.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q3 results beat expectations. Adjusted earnings per share were $3.82 versus the $3.73 analyst consensus, while revenue rose 10.3% year over year to $17.404 billion, ahead of the $17.32 billion estimate. Adjusted EPS more than doubled from the prior-year quarter. AbbVie Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: Immunology and neuroscience provided strong momentum. Skyrizi generated $5.776 billion in revenue and Rinvoq produced $2.706 billion, helping immunology revenue increase 16.3%. Neuroscience revenue climbed 19.4%, led by Vraylar, therapeutic Botox, Ubrelvy and Qulipta. AbbVie Lifts 2026 Outlook as Immunology, Neuroscience Quarterly Sales Beat Views
• Positive Sentiment: Management raised guidance and its dividend. AbbVie increased its 2026 adjusted EPS outlook to $13.95–$13.99 from $13.76–$13.96, despite including $0.69 per share of year-to-date acquired in-process research and development and milestone expenses. The company also announced a 5.2% dividend increase beginning with the February 2027 payment. AbbVie Raises FY26 Adjusted EPS Outlook and Boosts Dividend
• Positive Sentiment: Pipeline expansion supports longer-term confidence. AbbVie completed its acquisition of Apogee Therapeutics, strengthening its immunology pipeline, while Qulipta also outperformed topiramate in a Phase 3 migraine-prevention study. AbbVie QULIPTA Phase 3 Migraine Prevention Trial
• Negative Sentiment: Investors remain focused on valuation and concentration risks. Humira revenue fell 31.2% to $683 million, while aesthetics revenue declined 1.4%. After a substantial multiyear rally and trading near its 52-week high, analysts question whether additional valuation expansion is justified and how effectively AbbVie can sustain growth beyond Skyrizi and Rinvoq. Skyrizi and Rinvoq Dominate AbbVie Q3

About AbbVie

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.